Unit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, Italy.
Q J Nucl Med Mol Imaging. 2022 Sep;66(3):194-205. doi: 10.23736/S1824-4785.22.03463-X.
Advanced imaging techniques are needed to help clinicians in the diagnosis, in the choice of the right time for therapeutic interventions or for modifications and monitoring of treatment response in patients with autoimmune connective tissue diseases. Nuclear medicine imaging, especially PET/CT and PET/MRI, may play an important role in detecting disease activity, assessing early treatment response as well as in clarifying the complex mechanisms underlying systemic sclerosis, Sjögren's syndrome or systemic lupus erythematosus. In addition, [F]FDG PET/CT may help in excluding or detecting coexisting malignancies. Other more specific radiopharmaceuticals are being developed and investigated, targeting specific cells and molecules involved in connective tissue diseases. Further larger studies with standardized imaging protocol and image interpretation are strongly required before including PET/CT in the diagnostic work-up of subsets of patients with autoimmune connective tissue diseases.
需要先进的成像技术来帮助临床医生进行诊断,选择合适的治疗干预时间,或对自身免疫性结缔组织疾病患者的治疗反应进行调整和监测。核医学成像,特别是 PET/CT 和 PET/MRI,可能在检测疾病活动、评估早期治疗反应以及阐明系统性硬化症、干燥综合征或系统性红斑狼疮的复杂机制方面发挥重要作用。此外,[F]FDG PET/CT 有助于排除或检测共存的恶性肿瘤。正在开发和研究其他更具特异性的放射性药物,针对参与结缔组织疾病的特定细胞和分子。在将 PET/CT 纳入自身免疫性结缔组织疾病患者亚组的诊断工作中之前,需要进行更多具有标准化成像方案和图像解释的大型研究。